Across TCGA pan-cancer cohorts, RPL23P4 RNA is linked to patient survival in 17 of 34 cancer types, making it the most broadly survival-associated RPL23P4 data layer.
The strongest signal is observed in mesothelioma (MESO), where higher RPL23P4 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPL23P4 expression acts as an unfavorable survival marker, although some lineages such as UCS and DLBC show a favorable association.
MESO, ACC, and LIHC are the cancer types where RPL23P4 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.